EyePoint Pharmaceuticals, Inc.
EYPT
$11.84
-$0.20-1.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.99% | 12.04% | -5.97% | 7.50% | 34.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.99% | 12.04% | -5.97% | 7.50% | 34.98% |
| Cost of Revenue | 88.92% | 90.70% | 95.62% | 57.58% | 54.94% |
| Gross Profit | -179.41% | -203.91% | -304.30% | -136.94% | -83.53% |
| SG&A Expenses | 9.02% | 7.05% | 4.97% | -2.40% | -13.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.70% | 58.87% | 56.19% | 30.91% | 21.07% |
| Operating Income | -91.70% | -85.84% | -94.30% | -43.08% | -15.01% |
| Income Before Tax | -101.99% | -86.08% | -84.95% | -3.33% | 18.14% |
| Income Tax Expenses | 120.48% | 8.43% | 8.43% | -- | -- |
| Earnings from Continuing Operations | -102.00% | -86.00% | -84.86% | -3.42% | 18.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.00% | -86.00% | -84.86% | -3.42% | 18.06% |
| EBIT | -91.70% | -85.84% | -94.30% | -43.08% | -15.01% |
| EBITDA | -91.49% | -85.25% | -93.44% | -42.83% | -15.70% |
| EPS Basic | -49.11% | -31.81% | -25.87% | 24.76% | 36.56% |
| Normalized Basic EPS | -49.12% | -34.52% | -28.44% | 3.49% | 19.95% |
| EPS Diluted | -49.11% | -31.81% | -25.87% | 24.76% | 36.56% |
| Normalized Diluted EPS | -49.12% | -34.52% | -28.44% | 3.49% | 19.95% |
| Average Basic Shares Outstanding | 38.62% | 41.51% | 44.71% | 34.48% | 24.62% |
| Average Diluted Shares Outstanding | 38.62% | 41.51% | 44.71% | 34.48% | 24.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |